Detection of circulating vascular endothelial growth factor and matrix metalloproteinase‑9 in non‑small cell lung cancer 
using Luminex multiplex technology

Zhang,Ye; Wu,Jian‑Zhong; Zhang,Jun‑Ying; Xue,Jing; Ma,Rong; Cao,Hai‑Xia; Feng,Ji‑Feng

doi:10.3892/ol.2013.1718

Detection of circulating vascular endothelial growth factor and matrix metalloproteinase‑9 in non‑small cell lung cancer using Luminex multiplex technology

Authors:
- Ye Zhang
- Jian‑Zhong Wu
- Jun‑Ying Zhang
- Jing Xue
- Rong Ma
- Hai‑Xia Cao
- Ji‑Feng Feng
View Affiliations

Affiliations: Department of Chemotherapy, The Affiliated Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China, Research Center of Clinical Oncology, The Affiliated Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China, Department of Oncology, Xuzhou Medical College, Xuzhou, Jiangsu 221000, P.R. China, Nanjing University of Technology, Nanjing, Jiangsu 210008, P.R. China
Published online on: November 29, 2013 https://doi.org/10.3892/ol.2013.1718
Pages: 499-506

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been previously reported that vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)‑9 are important for the occurrence and development of non‑small cell lung cancer (NSCLC). The present study was designed to detect the serum levels of VEGF and MMP‑9 in NSCLC, and to explore their diagnostic and prognostic values. A total of 543 cases were involved, of which 332 were NSCLC (272 cases in the pretreatment group and 60 cases in the postoperative group), 91 were patients with benign lung diseases and 120 were healthy controls. The serum levels of VEGF and MMP‑9 were determined by Luminex multiplex technology. The serum levels of VEGF and MMP‑9 were found to be significantly higher in the pretreatment group than those in the patients with benign lung diseases and healthy controls (VEGF, P<0.0001; MMP‑9, P<0.0001). Compared with the pretreatment group, the serum levels of VEGF and MMP‑9 in the postoperative group were significantly decreased (VEGF, P=0.005; MMP‑9, P=0.002), and the levels of VEGF and MMP‑9 in the pretreatment group of patients with stages III and IV were higher than those with stages I and II (VEGF, P<0.0001; MMP‑9, P=0.021). In addition, the levels of VEGF and MMP‑9 were found to closely correlate with lymph node metastasis (VEGF, P<0.0001; MMP‑9, P<0.0001) in the pretreatment group, while being independent of other clinicopathological parameters (P>0.05). Furthermore, a positive correlation was observed between the serum levels of VEGF and MMP‑9 (r=0.159; P=0.009). A receiver operating characteristic curve analysis showed that the diagnostic value of MMP‑9 was higher than that of VEGF in the pretreatment group. The log‑rank test indicated that the inoperable NSCLC patients with low levels of VEGF exhibited a significantly longer overall survival time than those with high VEGF levels (P<0.0001). Additionally, the serum levels of VEGF and lymph node metastasis were identified as independent prognostic factors of the inoperable NSCLC patients in a multivariate Cox regression analysis (P<0.05). These results indicated that VEGF and MMP‑9 may be potential biomarkers for the diagnosis and prognosis of NSCLC.

View Figures

View References

1	Zhao P, Dai M, Chen W and Li N: Cancer trends in China. Jpn J Clin Oncol. 40:281–285. 2010. View Article : Google Scholar
2	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
3	Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
4	Kerbel RS: Tumor angiogenesis. N Engl J Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
5	Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
6	Hsu HY, Joos TO and Koga H: Multiplex microsphere-based flow cytometric platforms for protein analysis and their application in clinical proteomics-from assays to results. Electrophoresis. 30:4008–4019. 2009. View Article : Google Scholar : PubMed/NCBI
7	Hiratsuka S: Vasculogenensis, angiogenesis and special features of tumor blood vessels. Front Biosci (Landmark Ed). 16:1413–1427. 2011. View Article : Google Scholar : PubMed/NCBI
8	Zhang Y, Yu LK and Xia N: Evaluation of serum and pleural levels of endostatin and vascular epithelial growth factor in lung cancer patients with pleural effusion. Asian Pac J Trop Med. 5:239–242. 2012. View Article : Google Scholar
9	Muramatsu M, Yamamoto S, Osawa T and Shibuya M: Vascular endothelial growth factor receptor-1 signaling promotes mobilization of macrophage lineage cells from bone marrow and stimulates solid tumor growth. Cancer Res. 70:8211–8221. 2010. View Article : Google Scholar
10	Hiratsuka S, Nakamura K, Iwai S, et al: MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell. 2:289–300. 2002. View Article : Google Scholar : PubMed/NCBI
11	Bremnes RM, Camps C and Sirera R: Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer. 51:143–158. 2006. View Article : Google Scholar : PubMed/NCBI
12	Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V and Topuz E: Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. Cancer Invest. 24:576–580. 2006. View Article : Google Scholar : PubMed/NCBI
13	Jumper C, Cobos E and Lox C: Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Resp Med. 98:173–177. 2004. View Article : Google Scholar
14	Katsabeki-Katsafli A, Kerenidi T, Kostikas K, et al: Serum vascular endothelial growth factor is related to systemic oxidative stress in patients with lung cancer. Lung Cancer. 60:271–276. 2008. View Article : Google Scholar : PubMed/NCBI
15	Zheng S, Chang Y, Hodges KB, et al: Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival. Anticancer Res. 30:713–718. 2010.PubMed/NCBI
16	Yurdakul A, Akyürek N, Yilmaz Ş, Karakaya J, Memış L and Öztürk C: Prognostic impact of matrix metalloproteinases (MMP-9 and MMP-2) and vascular endothelial growth factor expression in non-small cell lung cancer. Turk J Med Sci. 42:281–288. 2012.
17	Tamura M, Oda M, Matsumoto I, et al: The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer. Ann Surg Oncol. 11:928–933. 2004. View Article : Google Scholar
18	Laack E, Köhler A, Kugler C, et al: Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol. 13:1550–1557. 2002. View Article : Google Scholar : PubMed/NCBI
19	Shimanuki Y, Takahashi K, Cui R, Hori S, Takahashi F, Miyamoto H and Fukurchi Y: Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung. 183:29–42. 2005. View Article : Google Scholar
20	Cox G, Jones JL and O’Byrne KJ: Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res. 6:2349–2355. 2000.PubMed/NCBI
21	Jin Y, Li JP, Tang LY, et al: Protein expression and significance of VEGF, EGFR and MMP-9 in non-small cell lung carcinomas. Asian Pac J Cancer Prev. 12:1473–1476. 2011.PubMed/NCBI
22	Hawinkels LJ, Zuidwijk K, Verspaget HW, et al: VEGF release by MMP-9 mediated heparansulphate cleavage induces colorectal cancer angiogenesis. Eur J Cancer. 44:1904–1913. 2008. View Article : Google Scholar : PubMed/NCBI
23	Jantus-Lewintre E, Sanmartín E, Sirera R, et al: Combined VEGF-A and VEGFR-2 concentrations in plasma: diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer. 74:326–331. 2011. View Article : Google Scholar : PubMed/NCBI
24	Atkinson JM, Pennington CJ, Martin SW, et al: Membrane type matrix metalloproteinases (MMPs) show differential expression in non-small cell lung cancer (NSCLC) compared to normal lung: correlation of MMP-14 mRNA expression and proteolytic activity. Eur J Cancer. 43:1764–1771. 2007. View Article : Google Scholar
25	Farhat FS, Tfayli A, Fakhruddin N, et al: Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Crit Rev Oncol Hematol. 84:149–160. 2012. View Article : Google Scholar : PubMed/NCBI
26	Chakra M, Pujol JL, Lamy PJ, et al: Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. J Thorac Oncol. 3:1119–1126. 2008. View Article : Google Scholar : PubMed/NCBI
27	Fujise N, Nanashima A, Taniguchi Y, et al: Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study. Lung Cancer. 27:19–26. 2000. View Article : Google Scholar : PubMed/NCBI
28	Martins SJ, Takagaki TY, Silva AGP, et al: Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma. Lung Cancer. 64:105–109. 2009. View Article : Google Scholar : PubMed/NCBI